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Protective potential of glucagon 
like peptide 2 (GLP-2) against the 
neurodegeneration 
Neurodegeneration consists in loss of neuron specific types, pattern 
and distribution, leading to progressive dysfunctions of the central ner-
vous system. Neurodegenerative diseases include diverse pathological 
conditions, among which Alzheimer’s and Parkinson’s diseases are the 
most prevalent ones. Alzheimer’s disease is known as a growing demen-
tia, characterized by progressive language, memory, and cognitive loss, 
while Parkinson’s disease is primarily characterized as a motor disorder. 
Senile plaques, caused by amyloid β peptide, hyperphosphorylated tau-
based neurofibrillary tangles and synapse loss, are the principal patho-
logical hallmarks of Alzheimer’s disease. Amyloid β oligomer formation 
is associated with development of reactive oxygen and nitrogen species, 
inflammation, calcium-dependent excitotoxicity, impairment of cellular 
respiration, and alteration of synaptic functions related with learning 
and memory. Parkinson’s disease is produced by dopaminergic neuron 
deterioration in the extrapyramidal tract of the midbrain. Accumula-
tion of α-synuclein proteins (Lewy bodies) in the central, autonomic, 
and peripheral nervous system is the hallmark of the Parkinson’s dis-
ease. The Levy bodies break the neuronal membrane leading to neu-
ronal death through oxidative stress, excitotoxicity, energy failure and 
neuroinflammation.
Factors associated with the development of neurodegenerative 
diseases: The development of neurodegenerative diseases may result 
from a number of factors including aging, genetics and environmental 
factors. In fact, at the cellular level, aging is associated with accumulat-
ing oxidative stress, declining mitochondrial function, impaired DNA 
repair and decreased tissue regeneration. As mitochondrial efficiency 
declines with age, the mitochondrial dysfunction may contribute to 
the formation of misfolded protein aggregates and subsequently may 
lead to Alzheimer’s and Parkinson’s diseases. In addition, neuronal 
death, due to activated microglia and astrocytes producing reactive 
oxygen species and pro-inflammatory cytokines, further will promote 
the activation of glial cells, developing a neurotoxic vicious cycle of in-
flammation that perpetuates tissue injury. However, the etiology of the 
neurodegenerative diseases is multifactorial. External factors, including 
lifestyle and diet, are linked with the risk of neurodegeneration. Meta-
bolic diseases, such as obesity and type 2 diabetes have been correlated 
with an increased probability of developing cognitive decline. Indeed, 
insulin has a significant role in modulation of synaptic plasticity and 
learning memory, then it plays a role in maintaining cognitive func-
tions. Alterations in the concentration of insulin and in the insulin 
receptor expression have been reported in Alzheimer’s disease brains, 
suggesting that irregularities in the insulin-signaling pathway may con-
tribute to impairment of memory function. Indeed, several evidences 
suggest that a high fat diet (HFD) can lead to obesity, insulin resistance 
and dementia. In HFD mice, the obesity is associated with peripheral 
and central insulin resistance, cerebral inflammation, increase in oxi-
dative stress and expression of amyloid β precursor protein, amyloid β, 
beta-secretase 1 and glycogen synthase kinase 3β (Nuzzo et al., 2015), 
enzymes involved in amyloid β precursor protein processing and for-
mation of amyloid plaques and neurofibrillary tangles, respectively. 
Therefore, HFD mice are used as a model to study the effects of poten-
tial beneficial factors for neurodegeneration, because they show in the 
cortex increased markers of Alzheimer’s disease, formation of plaques 
as well as impaired spatial learning (Valladolid-Acebes et al., 2011; 
Nuzzo et al., 2015; Wu et al., 2018). Vascular pathology also contributes 
to neurodegenerative disorders and vascular risk factors aggravate cog-
nitive impairment in different chronic neurodegenerative disease. Loss 
of brain-blood barrier integrity results in increased vascular permeabil-
ity and it is associated with reduced cerebral blood flow and impaired 
haemodynamic responses. Breakdown of the brain-blood barrier en-
ables toxic blood-derived molecules, cells and microbial agents to enter 
the brain, triggering inflammatory and immune responses, involved in 
the neurodegeneration. Continuously reduced blood supply in brains 
contributes to a decrease in brain metabolism and causes a series of 
endogenous neuronal changes. Chronic cerebral hypoperfusion (CCH) 
has been shown to potentiate amyloid pathology and to induce microg-
lia activation, and blood-brain barrier disruption. In CCH, autophagy 
signaling is activated, provoking neuroinflammation and oxidative 
stress, amyloid β protein accumulation and tau hyperphosphorylation, 
with cognition impairment (Back et al., 2017).
Glucagon like peptide 2 (GLP-2) and neurodegeneration: Recently 
significant decrease in hippocampal levels of GLP-2 receptor (GLP-
2R) has been reported after CCH in rats, suggesting that this may be 
related to cognitive impairment induced by blood low perfusion (Xie 
et al., 2018). Moreover, upregulation of GLP-2R expression can rescue 
the cognitive impairment induced by CCH (Xie et al., 2018). This find-
ing together with other recent evidence lead to consider GLP-2 as a 
protective and improving memory factor. Indeed, GLP-2 had no effect 
on memory function in normal mice, but the peptide protects and im-
proves memory function in mice injected with intracerebroventricular 
lipopolysaccharides, which induces neuroinflammation and pro-in-
flammatory cytokine expression increase (Iwai et al., 2015). Moreover, 
injections of GLP-2 improve the learning and memory ability in mice 
with vascular dementia (Chi et al., 2017). GLP-2 is a 33-amino-acid 
peptide, which is synthesized not only in L-cells of the small intestine 
and colon, but also in a discrete population of neurons in the brainstem 
and hypothalamus. The GLP-2R, a G protein-coupled receptor, which 
is widely expressed in the gut, has been localized also within the central 
nervous system including the hypothalamus, hippocampus and cortex. 
Although different biological actions have been described in the gut, 
the role of GLP-2 in the central nervous system is less known, because 
few researches investigated the role of GLP-2 in the nervous system. 
The first studies in vitro suggested that the GLP-2R activation protects 
neurons from excitotoxic damage, because it is able to reduce the gluta-
mate-induced cell death in cultured hippocampal cells (Lovshin et al., 
2004) and it acts as a trophic factor for astrocytes, because it enhances 
the proliferation of these cells (Velázquez et al., 2009). In vivo studies 
suggested that the central administration of GLP-2 to rodents decreased 
gut motility and blood pressure, suppressed food intake, suggesting 
that the peptide may act as a satiation signal to the hypothalamus, and 
produced antidepressant-like effects. Moreover, intracerebroventricular 
infusion of GLP-2 increased glucose tolerance and insulin sensitivity by 
activating GLP-2R and intracellular phosphatidylinositol 3-kinase-de-
pendent signaling pathways in proopiomelanocortin expressing neu-
rons (Shi et al., 2013) (Figure 1). Indeed, GLP-2 may act as a protective 
factor against the deregulation of the glucose metabolism that occurs 
in obese conditions, at least in animal model (Baldassano et al., 2015), 
condition which could lead to neurodegeneration (Nuzzo et al., 2015). 
Mice lacking GLP-2R selectively in hypothalamic arcuate nucleus 
proopiomelanocortin neurons display impaired postprandial glucose 
tolerance and hepatic insulin resistance suggesting a GLP-2 physiolog-
ical role in glycaemic control. The GLP-2 beneficial action on central 
insulin sensitivity could be beneficial for neurodegeneration because 
when impairment of insulin signaling occurs, protein kinase B (Akt) is 
down-phosphorylated and Foxo3a translocates from the cytoplasm to 
the nucleus where it activates its pro-apototic target genes. A variety of 
other biological activities, however, could be interpreted as suggesting 
a neuroprotective role in the brain (Figure 1). In cultured hippocampal 
neurons GLP-2R activation acutely and dose-dependently stimulates de 
novo synthesis of protein by the phosphatidylinositol 3-kinase-depen-
dent Akt-mammalian target of rapamycin (mTOR) signaling pathway 
(Shi et al., 2012). mTOR is a key downstream effector of phosphati-
dylinositol 3-kinase-dependent Akt, involved in the regulation of cell 
growth, proliferation, and survival, protein synthesis, and angiogenesis. 
Therefore, GLP-2-induced stimulation of protein synthesis might be 
physiologically relevant to providing secondary mediators (neuropep-
tides or growth factors) and to maintaining neuronal survival. Xie et al. 
(2018) analyzed not only how GLP2-R is involved in the development 
of learning and memory impairment caused by CCH, but also the un-
derlying mechanisms. The results from their experiments suggest that 
GLP-2R over-expression can improve the impairment of long-term 
potentiation and long-term depression, and consequently the cognitive 
damage induced by CCH. GLP-2R downregulation may be involved 
in CCH-induced cognitive impairment by inhibiting synaptic plas-
ticity via decreased AKT-mTOR signaling. This phosphatidylinositol 
3-kinase-AKT-mTOR-p70S6K pathway is involved in synapse-related 
protein synthesis, synaptic plasticity, long-term potentiation, long-term 
depression, neurogenesis, and memory formation in hippocampus. 
Indeed, GLP-2R increases the neurogenesis in the dentate gyrus, neu-
ronal activity, and density of dendritic spines and mushroom spines in 
hippocampal neurons (Figure 1). Further recent direct evidences for 
a protective and beneficial role in the brain have been reported in the 
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animal model (Figure 1) (Nuzzo et al., 2019). GLP-2 is able to exert 
anti-inflammatory and anti-oxidative activities in the central nervous 
system. Brains of HFD mice, treated for four weeks with the stable 
analogue of the GLP-2, [Gly2]-GLP-2 (teduglutide), show reductions 
in several inflammation and stress markers (nuclear factor-kappa B, 
interleukin-8, tumor necrosis factor-α, interleukin-1β and interleu-
kin-6, phosphorylated extracellular regulated protein kinases, heat 
shock protein 60, inducible nitric oxide synthase) as well as the reactive 
oxygen species genesis in comparison with the brain of HFD-untreat-
ed mice. Moreover, [Gly2]-GLP-2 inhibits the increased expression of 
GFAP, considered as index of gliosis and glia activation, observed in 
superficial and deep areas of the cortex of HFD mice. Therefore, the 
peptide could minimize the deleterious inflammatory effects induced 
by HFD. In addition, [Gly2]-GLP-2 reduces the presence of neurons 
with fragmented DNA in brain cortex sections. In fact, the increase 
in the cell number with fragmented DNA, index of an impairment of 
cell survival, which is present in the cortical superficial and deep areas 
of the HFD untreated-animals, has not been observed in the [Gly2]-
GLP-2-treated HFD mice, suggesting a preventive role of the peptide in 
inducing apoptosis (Nuzzo et al., 2019) (Figure 1). [Gly2]-GLP-2 treat-
ment significantly reduces the HFD-induced increase in the expression 
of amyloid β precursor protein without modifying the expression levels 
of beta-secretase 1 and PSN1, enzymes involved in amyloid β precursor 
protein processing, suggesting that these enzymes are not involved in 
amyloid β precursor protein processing yet, likely due to the age of mice 
used for the experiments. Therefore, whether endogenous or exogenous 
central nervous system GLP-2R signaling modulates actions specifically 
involved in Alzheimer’s disease development requires additional inves-
tigation.
Conclusion and perspectives: Although recent evidence underlines the 
importance of GLP-2 and GLP-2R in neuroprotection in animal model, 
we are still far from having an in depth understanding of the complex 
neurobiology of GLP-2. At this time, much remains to be done to 
characterize fully the functional roles and signaling events of GLP-2 in 
the brain. In particular, additional studies are required to validate and 
define the peptide involvement under neurodegenerative conditions. 
These studies may shed light on new approaches to promote neuronal 
regeneration and repair following injury or disease.
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Figure 1 Putative actions responsible for the  beneficial effects 
of glucagon like peptide 2 (GLP-2) in the neurodegeneration.
Exogenous GLP-2 is able to reduce the expression of markers of 
inflammation and stress, the glia activation and the apoptosis in 
the brains of high fat diet mice. Intracerebroventricular infusion 
of GLP-2 increases glucose tolerance and insulin sensitivity by 
activating GLP-2 receptor (GLP-2R) and intracellular phospha-
tidylinositol 3-kinase (PI3K)-dependent signaling pathways in 
proopiomelanocortin expressing neurons. In cultured hippocam-
pal neurons, GLP-2R activation acutely and dose-dependently 
stimulates de novo synthesis of protein by the phosphatidylinositol 
3-kinase-dependent protein kinase B (Akt)-mammalian target of 
rapamycin (mTOR) signaling pathway. GLP-2R over-expression 
improves the impairment of long-term potentiation (LTP) and 
long-term depression (LTD) and it increases the neurogenesis 
in the dentate gyrus, neuronal activity, and density of dendritic 
spines and mushroom spines in hippocampal neurons. p-ERK: 
Phosphorylated extracellular regulated protein kinases; Hsp60: 
heat shock protein 60; iNOS: inducible nitric oxide synthase; IL: 
interleukin; TNF-α: tumor necrosis factor-α; NFkB: nuclear fac-
tor-kappa B; GFAP: glial fibrillary acidic protein; ROS: reactive 
oxygen species.
